Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators
- Published on 7th October 2022 by Autifony Therapeutics
Autifony to present preclinical data supporting the efficacy of its novel clinical-stage Kv3 modulators to address cellular dysfunction, ataxia, and seizure susceptibility in PME (Progressive Myoclonic Epilepsy, EPM7) at the American Epilepsy Society (AES) Annual Meeting, taking place 2-6 December 2022 in Nashville, Tennessee.
Other news
-
LifeArc: £3m fund to accelerate development of new CF therapiesPublished on 16 Mar 2023 -
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidatePublished on 14 Mar 2023 -
Thermo Fisher Scientific simplifies trace elemental analysis in environmental, food, pharmaceutical and industrial testing labsPublished on 8 Mar 2023 -
Cytiva and TerraCycle expand first-of-its kind recycling programPublished on 8 Mar 2023
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.